24-Apr-2026
Thermo Fisher ranks sixth by Quant as stock falls on Q1 results
Seeking Alpha News (Thu, 23-Apr 7:54 AM ET)
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
PRNewswire (Sat, 18-Apr 10:00 PM ET)
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
PRNewswire (Wed, 15-Apr 4:05 PM ET)
PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas
PRNewswire (Tue, 17-Mar 8:00 AM ET)
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference
PRNewswire (Thu, 19-Feb 4:05 PM ET)
PRNewswire (Thu, 12-Feb 4:05 PM ET)
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
PRNewswire (Wed, 4-Feb 9:00 AM ET)
Market Chameleon (Mon, 12-Jan 4:17 AM ET)
10x Genomics Projects Sequential Revenue Growth Despite Ongoing Operating Losses
Market Chameleon (Fri, 7-Nov 6:19 AM ET)
10x Genomics’ Next-Gen Chromium Flex Sets New Standard for Scalable Single Cell Research
Market Chameleon (Wed, 29-Oct 5:54 AM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of April 24, 2026, TXG stock price climbed to $22.08 with 1,394,026 million shares trading.
TXG has a beta of 1.78, meaning it tends to be more sensitive to market movements. TXG has a correlation of 0.13 to the broad based SPY ETF.
TXG has a market cap of $2.82 billion. This is considered a Mid Cap stock.
Last quarter 10X Genomics reported $166 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.03.
In the last 3 years, TXG traded as high as $63.57 and as low as $6.78.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): ARKK, VTI, ARKG, VB, IWM.
TXG has outperformed the market in the last year with a return of +165.7%, while the SPY ETF gained +31.9%. However, in the most recent history, TXG shares have underperformed the stock market with its stock returning -1.3% in the last 3 month period and -5.1% for the last 2 week period, while SPY has returned +3.8% and +5.1%, respectively.
TXG support price is $20.53 and resistance is $22.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.
